1. Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner. (1st January 2021) Authors: Xia, Wenjiao; Qi, Xin; Li, Mingfeng; Wu, Yu; Sun, Lulu; Fan, Xinglong; Yuan, Yuan; Li, Jing Journal: Oncoimmunology Issue: Volume 10:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Issue 15 (3rd April 2019) Authors: Zhang, Huiyong; Jia, Enchao; Xia, Wenjiao; Lv, Tanyu; Lu, Chengui; Xu, Zhenping; Zhu, Wuling Journal: Vaccine Issue: Volume 37:Issue 15(2019) Page Start: 2090 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. VEGF165b and its mutant demonstrate immunomodulatory, not merely anti-angiogenic functions, in tumor-bearing mice. (June 2020) Authors: Zhang, Huiyong; Xia, Wenjiao; Liang, Chen; Wang, Xiaoyin; Zhi, Lingtong; Guo, Changjiang; Niu, Zhiyuan; Zhu, Wuling Journal: Molecular immunology Issue: Volume 122(2020:Jun.) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. VEGF165b augments NK92 cytolytic activity against human K562 leukemia cells by upregulating the levels of perforin and granzyme B via the VEGR1-PLC pathway. (December 2020) Authors: Wang, Xiaoyin; Liang, Chen; Xia, Wenjiao; Guo, Changjiang; Niu, Zhiyuan; Zhu, Wuling; Zhang, Huiyong Journal: Molecular immunology Issue: Volume 128(2020:Dec.) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗